No information is available on the clinical use of sotorasib during breastfeeding. Because sotorasib is 89% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during sotorasib therapy and for 1 week after the last dose.
关于索托拉西布在母乳喂养期间的临床应用尚无可用信息。由于索托拉西布与血浆蛋白的结合率为89%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿的潜在毒性，制造商建议在索托拉西布治疗期间及最后一剂后1周内停止母乳喂养。
